Perruzza, Lisa
Heckmann, Julia
Rezzonico Jost, Tanja
Raneri, Matteo
Guglielmetti, Simone
Gargari, Giorgio
Palatella, Martina https://orcid.org/0000-0003-1986-8590
Willers, Maike https://orcid.org/0000-0002-8190-273X
Fehlhaber, Beate
Werlein, Christopher https://orcid.org/0000-0002-7694-4257
Vogl, Thomas https://orcid.org/0000-0001-9669-7479
Roth, Johannes https://orcid.org/0000-0001-7035-8348
Grassi, Fabio https://orcid.org/0000-0003-3348-1712
Viemann, Dorothee https://orcid.org/0000-0002-9009-3559
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-004078)
Bill and Melinda Gates Foundation (INV-004078)
Bundesministerium für Bildung und Forschung (01EK2103A)
Bundesministerium für Bildung und Forschung (01EK2103D)
Deutsche Forschungsgemeinschaft (VI 538/6-3, VI 538-9-1, 492620490, 491676693, 390874280)
Bill and Melinda Gates Foundation
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_192531)
Article History
Received: 19 December 2023
Accepted: 19 September 2024
First Online: 4 October 2024
Competing interests
: F.G. is the founder of MV BioTherapeutics, a company developing mucosal vaccines and biotherapeutics. All remaining authors declare no conflicts of interest.